2022
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Bernard-Raichon L, Venzon M, Klein J, Axelrad J, Zhang C, Sullivan A, Hussey G, Casanovas-Massana A, Noval M, Valero-Jimenez A, Gago J, Putzel G, Pironti A, Wilder E, Thorpe L, Littman D, Dittmann M, Stapleford K, Shopsin B, Torres V, Ko A, Iwasaki A, Cadwell K, Schluter J. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nature Communications 2022, 13: 5926. PMID: 36319618, PMCID: PMC9626559, DOI: 10.1038/s41467-022-33395-6.Peer-Reviewed Original ResearchConceptsGut microbiome dysbiosisCOVID-19 patientsMicrobiome dysbiosisSecondary infectionSARS-CoV-2 infection inducesLife-threatening secondary infectionsTranslocation of bacteriaBlood culture resultsCOVID-19 severityAntimicrobial-resistant speciesCOVID-19Different clinical sitesMicrobial translocationBloodstream infectionsInfection inducesBarrier permeabilitySystemic circulationDysbiosisGoblet cellsPaneth cellsClinical sitesCulture resultsPatient healthGut microbiomePatients
2021
Maternal outcomes and risk factors for COVID-19 severity among pregnant women
Vouga M, Favre G, Martinez-Perez O, Pomar L, Acebal LF, Abascal-Saiz A, Hernandez MRV, Hcini N, Lambert V, Carles G, Sichitiu J, Salomon L, Stirnemann J, Ville Y, de Tejada BM, Goncé A, Hawkins-Villarreal A, Castillo K, Solsona EG, Trigo L, Cleary B, Geary M, Bartels H, Al-Kharouf F, Malone F, Higgins M, Keating N, Knowles S, Poncelet C, Ribeiro-do-Valle CC, Surita F, Dantas-Silva A, Borrelli C, Luz AG, Fuenzalida J, Carvajal J, Canales MG, Hernandez O, Grechukhina O, Ko AI, Reddy U, Figueiredo R, Moucho M, Pinto PV, De Luca C, De Santis M, de Campos DA, Martins I, Garabedian C, Subtil D, Bohrer B, Da Rocha Oppermann ML, Wender MCO, Schuler-Faccini L, Sanseverino MTV, Giugliani C, Friedrich L, Scherer MH, Mottet N, Ducarme G, Pelerin H, Moreau C, Breton B, Quibel T, Rozenberg P, Giannoni E, Granado C, Monod C, Mueller D, Hoesli I, Bassler D, Heldstab S, Kölble NO, Sentilhes L, Charvet M, Deprest J, Richter J, Van der Veeken L, Eggel-Hort B, Plantefeve G, Derouich M, Calvache AJN, Lopez-Giron MC, Burgos-Luna JM, Escobar-Vidarte MF, Hecher K, Tallarek AC, Hadar E, Haratz KK, Amikam U, Malinger G, Maymon R, Yogev Y, Schäffer L, Toussaint A, Rossier MC, De Sa RAM, Grawe C, Aebi-Popp K, Radan AP, Raio L, Surbek D, Böckenhoff P, Strizek B, Kaufmann M, Bloch A, Boulvain M, Johann S, Heldstab SA, Bernasconi MT, Grant G, Feki A, Brochut AM, Giral M, Sedille L, Papadia A, Brugger RC, Weber B, Fischer T, Kahlert C, Saines KN, Cambou M, Kanellos P, Chen X, Yin M, Haessig A, Ackermann S, Baud D, Panchaud A. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Scientific Reports 2021, 11: 13898. PMID: 34230507, PMCID: PMC8260739, DOI: 10.1038/s41598-021-92357-y.Peer-Reviewed Original ResearchConceptsSevere maternal outcomesPregnant womenRisk factorsMaternal outcomesPulmonary comorbiditiesHypertensive disordersNeonatal outcomesSevere complicationsHigh riskSevere acute respiratory syndrome coronavirus 2Severe coronavirus disease-19Severe COVID-19 diseaseAcute respiratory syndrome coronavirus 2Neonatal intensive care unitSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Immediate neonatal outcomeIntensive care unitSyndrome coronavirus 2COVID-19 severityCase-control studyCoronavirus disease-19SARS-CoV-2COVID-19 diseaseMaternal disease